CA2012867A1 - Depsipeptides cycliques cytotoxiques nouveaux isoles du tunicier trididemnum solidum - Google Patents

Depsipeptides cycliques cytotoxiques nouveaux isoles du tunicier trididemnum solidum

Info

Publication number: CA2012867A1
Authority: CA; Canada
Prior art keywords: cyclic depsipeptides; novel cytotoxic; trididemnum solidum; cytotoxic cyclic; tunicate
Prior art date: 1989-04-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2012867A

Other languages

English (en)

Other versions

CA2012867C (fr

Inventor

Kenneth L. Rinehart, Jr.

Ryuichi Sakai

Justin G. Stroh

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Illinois

Original Assignee

University of Illinois

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-04-10

Filing date

1990-03-22

Publication date

1990-10-10

1990-03-22 Application filed by University of Illinois filed Critical University of Illinois

1990-10-10 Publication of CA2012867A1 publication Critical patent/CA2012867A1/fr

1999-09-21 Application granted granted Critical

1999-09-21 Publication of CA2012867C publication Critical patent/CA2012867C/fr

2010-03-22 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

241000804473 Trididemnum solidum Species 0.000 title abstract 2
230000001472 cytotoxic effect Effects 0.000 title abstract 2
108010002156 Depsipeptides Proteins 0.000 title 1
231100000433 cytotoxic Toxicity 0.000 title 1
KYHUYMLIVQFXRI-XYUQHQMCSA-N (2s)-n-[(2r)-1-[[(3s,6s,8s,12s,13r,16s,17r,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trimethyl-3-(2-methylpropyl)-2,5,7,10,15,19,22-heptaoxo-8-propan-2-yl-9,18-dioxa-1,4,14,21-tetrazabicyclo[21.3.0]hexacosan-16-yl]amino Chemical class CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)O KYHUYMLIVQFXRI-XYUQHQMCSA-N 0.000 abstract 1
GXKAOWYTJPGGBI-BHTIDRDUSA-N (4s)-4-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(3r)-3-hydroxydecanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-[(2s)-1-[(2s)-2-[[(2r)-1-[[(3s,6s,8s,12s,13s,16s,17s,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20- Chemical compound CCCCCCC[C@@H](O)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)O[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N(C)[C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)[C@@H](O)CC(=O)O[C@@H](C(C)C)C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C GXKAOWYTJPGGBI-BHTIDRDUSA-N 0.000 abstract 1
BUHGEDVBBOQECR-HGESRAKOSA-N (4s)-4-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(3r)-3-hydroxydecanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-5-[(2s)-1-[(2s)-2-[[(2r)-1-[[(3s,6s,8s,12s,13s,16s,17s,20s,23s)-13-[(2s)-butan-2-yl]-12-hydroxy-20-[(4-methoxyphenyl)methyl]-6,17,21-trime Chemical compound CCCCCCC[C@@H](O)CC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)O[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N(C)[C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)[C@@H](O)CC(=O)O[C@@H](C(C)C)C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@H]1C BUHGEDVBBOQECR-HGESRAKOSA-N 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
229940041181 antineoplastic drug Drugs 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K11/00—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K11/02—Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

CA002012867A 1989-04-10 1990-03-22 Depsipeptides cycliques cytotoxiques nouveaux isoles du tunicier trididemnum solidum Expired - Fee Related CA2012867C (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US07/335,903 US4948791A (en)	1989-04-10	1989-04-10	Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US335,903		1989-04-10

Publications (2)

Publication Number	Publication Date
CA2012867A1 true CA2012867A1 (fr)	1990-10-10
CA2012867C CA2012867C (fr)	1999-09-21

Family

ID=23313708

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002012867A Expired - Fee Related CA2012867C (fr)	1989-04-10	1990-03-22	Depsipeptides cycliques cytotoxiques nouveaux isoles du tunicier trididemnum solidum

Country Status (10)

Country	Link
US (1)	US4948791A (fr)
EP (1)	EP0393883B1 (fr)
JP (1)	JP3431920B2 (fr)
AT (1)	ATE183751T1 (fr)
AU (1)	AU640130B2 (fr)
CA (1)	CA2012867C (fr)
DE (1)	DE69033257T2 (fr)
DK (1)	DK0393883T3 (fr)
ES (1)	ES2140373T3 (fr)
GR (1)	GR3031846T3 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030148933A1 (en)	1990-10-01	2003-08-07	Pharma Mar S.A.	Derivatives of dehydrodidemnin B
DE4120327A1 (de) *	1991-06-20	1992-12-24	Basf Ag	Neue peptide, ihre herstellung und verwendung
US6156724A (en) *	1996-06-07	2000-12-05	Rinehart; Kenneth L.	Uses of didemnins as immunomodulating agents
US5830996A (en) *	1996-09-27	1998-11-03	University Of Utah Research Foundation	Cyclic peptide antitumor agent from an ascidian
EP0973518B1 (fr) *	1996-10-24	2006-03-29	The Board Of Trustees Of The University Of Illinois	Procedes semi-synthetiques de preparation d'analogues de didemnine
US6034058A (en) *	1997-04-15	2000-03-07	Rinehart; Kenneth L.	Semi-synthetic alanyl dilemnin analogs
GB9803448D0 (en)	1998-02-18	1998-04-15	Pharma Mar Sa	Pharmaceutical formulation
UA76718C2 (uk)	2000-06-30	2006-09-15	Фарма Мар, С.А.	Протипухлинні похідні аплідину
BR0114604A (pt)	2000-10-12	2003-10-14	Pharma Mar Sa	Tratamento de cnceres
DK1603584T3 (da)	2003-03-12	2009-01-05	Dana Farber Cancer Inst Inc	Aplidine til behandling af multipelt myelom
US7576188B2 (en)	2003-03-12	2009-08-18	Pharma Mar, S.A.U.	Antitumoral treatments
RS54928B1 (sr)	2006-02-28	2016-10-31	Pharma Mar Sa	Poboljšano lečenje multiplog mijeloma
JOP20190254A1 (ar)	2017-04-27	2019-10-27	Pharma Mar Sa	مركبات مضادة للأورام

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2576022B1 (fr) *	1985-01-11	1987-09-11	Rhone Poulenc Sante	Nouveaux derives de la pristinamycine ii b, leur preparation et les compositions pharmaceutiques qui les contiennent

1989
- 1989-04-10 US US07/335,903 patent/US4948791A/en not_active Expired - Lifetime
1990
- 1990-03-22 CA CA002012867A patent/CA2012867C/fr not_active Expired - Fee Related
- 1990-04-05 DK DK90303672T patent/DK0393883T3/da active
- 1990-04-05 AT AT90303672T patent/ATE183751T1/de not_active IP Right Cessation
- 1990-04-05 ES ES90303672T patent/ES2140373T3/es not_active Expired - Lifetime
- 1990-04-05 DE DE69033257T patent/DE69033257T2/de not_active Expired - Fee Related
- 1990-04-05 EP EP90303672A patent/EP0393883B1/fr not_active Expired - Lifetime
- 1990-04-09 AU AU53053/90A patent/AU640130B2/en not_active Ceased
- 1990-04-10 JP JP09327490A patent/JP3431920B2/ja not_active Expired - Fee Related
1999
- 1999-11-16 GR GR990402940T patent/GR3031846T3/el unknown

Also Published As

Publication number	Publication date
AU640130B2 (en)	1993-08-19
DE69033257D1 (de)	1999-09-30
ES2140373T3 (es)	2000-03-01
ATE183751T1 (de)	1999-09-15
DK0393883T3 (da)	2000-03-20
AU5305390A (en)	1990-10-11
US4948791A (en)	1990-08-14
EP0393883B1 (fr)	1999-08-25
GR3031846T3 (en)	2000-02-29
DE69033257T2 (de)	2000-04-13
EP0393883A1 (fr)	1990-10-24
JPH03135999A (ja)	1991-06-10
JP3431920B2 (ja)	2003-07-28
CA2012867C (fr)	1999-09-21

Legal Events

Date	Code	Title	Description
1993-09-27	EEER	Examination request
2008-03-25	MKLA	Lapsed

Publication	Publication Date	Title
GB8922026D0 (en)	1989-11-15	Novel anti-viral and cytotoxic agent
PH31059A (en)	1998-02-05	Pharmaceutical compositions comprising cyclosporins.
AU640130B2 (en)	1993-08-19	Novel cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
EP0595133A3 (fr)	1998-11-04	Prodroques, leur préparation, et utilisation comme médicaments
IL88898A0 (en)	1989-08-15	1,2-bis(aminomethyl)-cyclo-butane-platinum complexes,their preparation and pharmaceutical compositions containing them
EP0353678A3 (fr)	1991-03-20	Dérivés FR-901154 et FR-901155, procédé pour leur production
IE930197L (en)	1987-12-11	Anti-Inflammatory Compositions
AU3885689A (en)	1990-01-25	Selectively o-acylated glycosaminoglycans, their preparation and pharmaceutical compositions containing them
AU6963491A (en)	1991-06-13	Antihemostatic factor vii peptides
NZ220379A (en)	1989-02-24	Immunosuppressant cyclodepsipeptides from streptomyces sp. s-16328
EP0297594A3 (fr)	1990-07-25	Dérivés glucosidiques de l'épipodophyllotoxine substitués par des atomes d'azote en position 3' et 4'
AU664101B2 (en)	1995-11-02	Novel phospholipid derivatives
TW221692B (fr)	1994-03-11
AU8184291A (en)	1992-03-02	1,4-benzodioscane derivatives, process for the preparation thereof and pharmaceutical compositions therefrom
EP0548376A4 (fr)	1994-02-02
EP0264017A3 (en)	1989-11-15	Pharmaceutical compositions having healing activity
IL82705A0 (en)	1987-11-30	Pharmaceutical compositions containing avarone,avarol or derivatives thereof for the control of adult t-cell leukemia/lymphoma
ZA89424B (en)	1990-09-26	Tetrahydrophyridine derivatives
AU8766591A (en)	1992-05-26	Assay for cyclic 1,2-dithiol-3-ones
NZ230418A (en)	1991-10-25	Substituted 4-azatricyclo (22.3.1.0 4,9 ) octacos-18-ene derivatives, preparation from streptomyces culture, and pharmaceutical compositions
UA15644A (uk)	1997-06-30	Клей для склеюваhhя робочих елемеhтів іhфрачервоhих систем
IE900683L (en)	1990-08-27	Peptide lactones.